Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
23
-
Total 13F shares, excl. options
-
1,344,999
-
Shares change
-
+33,536
-
Total reported value, excl. options
-
$4,391,761
-
Value change
-
+$109,510
-
Put/Call ratio
-
467%
-
Number of buys
-
9
-
Number of sells
-
-8
-
Price
-
$3.26
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q4 2023
28 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q4 2023.
Gain Therapeutics, Inc. - COM (GANX) has 23 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,344,999 shares
.
Largest 10 shareholders include GREENLIGHT CAPITAL INC (588,410 shares), GEODE CAPITAL MANAGEMENT, LLC (151,476 shares), CM Management, LLC (90,000 shares), VANGUARD GROUP INC (88,385 shares), CITADEL ADVISORS LLC (65,394 shares), PRELUDE CAPITAL MANAGEMENT, LLC (58,100 shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (46,100 shares), NORTHERN TRUST CORP (43,513 shares), RENAISSANCE TECHNOLOGIES LLC (42,800 shares), and SUSQUEHANNA INTERNATIONAL GROUP, LLP (34,500 shares).
This table shows the top 23 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.